Shaily Engineering Plastics Ltd

- The company anticipates significant growth, targeting approximately 60% growth in the healthcare (pharma) business for the current financial year (FY '24), with sustainable margin improvements expected as this segment expands. - Revenue from the pharma business is expected to double over a three-year horizon (by FY '26/'27) driven by new capacity and increased volume. - New business wins, including from longstanding client GE Appliances and home furnishings, are expected to contribute incremental revenue starting Q4 FY '24 and Q1 FY '25. - Overall EBITDA margins have shown improvement, with a 290 bps increase in Q1 FY '24, and further margin enhancement is expected over a 3-year perspective as pharma business grows. - Utilization levels are projected to improve gradually; around 50-55% utilization expected in FY '24 with further increases in FY '25, supporting improved profitability. - Earnings growth is guided by doubling revenues in key segments and improved operational efficiencies rather than per-ton gross profit targets.

- Awarded new business from General Electric (GE Appliances) valued at INR 40 crores per annum; signifies a strong and long-standing relationship since 1995 with growing opportunities. - Received business confirmations for 3 new home furnishing products, totaling INR 50 crores per annum, enhancing relationship and utilization. - Added 3 new products in the automotive and engineering segments contributing to growth. - Incremental business of INR 90 crores expected to flow in from Q4 FY '24 and Q1 FY '25 onwards, accretive at EBITDA level without significant incremental capex. - Focus on building new strategic businesses in healthcare, consumer electronics, and industrial applications, with some projects in early stages. - The company refrains from giving precise utilization or revenue guidance for orders but anticipates gradual growth and ramp-up over 18 to 30 months horizon.

- There is no specific mention of any current or planned fundraising through debt or equity in the provided transcript from the Q1 FY24 earnings call. - Discussions focused on existing investments, capacity expansions, and business growth rather than new funding rounds. - The company has already utilized funds raised in 2021 for enhancing capacities and building new healthcare facilities. - No guidance or indication was provided about seeking additional debt or equity financing in the near term.

- Current year capex primarily focused on pharma facility and tool room; no large capex beyond this planned for the current year. (Page 17) - Major pharma capex expected to complete between Q2 and Q3 of FY '24. (Page 8) - Ramp-up of pharma facility expected over the next 4 to 6 quarters, with full utilization likely by the second half of FY '25. (Page 8) - Post-improvement in utilization, future capex plans will depend on how utilization levels improve in other business segments. (Page 17) - No incremental tooling capex anticipated for the INR 90 crore incremental orders; these orders are accretive at EBITDA and ROCE levels. (Page 15) - Pharma investments made recently are aimed at accelerating faster revenue growth with increased IP contribution. (Pages 3, 8)

- Targeting a 60-70% growth in healthcare revenue for the current financial year, indicating a substantial ramp-up in the pharma segment. - Expecting to double overall revenue in the next 3 years, supported by increased capacity and new product launches. - Pharma business projected to grow faster than the overall business, leading to margin improvement over a 3-year horizon. - Adding capacity to manufacture an additional 20 million pens, with volume ramp-up expected over FY '24 to FY '26. - Gradual improvement in utilization levels anticipated: - Current utilization expected around 50-55% for FY '24, with gradual improvement over the year. - Full utilization of new pharma facilities likely by second half of FY '25. - New orders and products (e.g., GE Appliances, home furnishing) to contribute to growth starting Q4 FY '24 and FY '25. - UK subsidiary foresees 2-3x revenue growth in the current financial year.